Inspiring Insights from Prof. Dr. Halil Özcan on Vagus Nerve Stimulation🌟 It's been two months since our enlightening conversation with Prof. Dr. Halil Özcan, Head of the Department of Psychiatry at Atatürk University in Erzurum, Turkey. Prof. Özcan has been at the forefront of numerous successful treatments with our tVNS ® Vagus Nerve Stimulation Device since 2021. During our discussion, Prof. Özcan shared invaluable experiences and insights into vagal nerve stimulation and its diverse applications across various indications. He recounted remarkable stories of recovery, notably highlighting exceptional improvements in coma patients after receiving treatment. With over two decades of research in clinical studies worldwide, Prof. Özcan's pioneering work has paved the way for the use of vagus nerve stimulation in treating conditions such as depression, anxiety disorders, and sleep problems, yielding positive outcomes at Neuromodulation centers. His positive experiences with chronic migraine and tinnitus patients offer hope for millions facing similar challenges, showcasing the potential of vagal nerve stimulation to revolutionize healthcare as a low side-effect option for various conditions. We extend our heartfelt gratitude to Prof. Dr. Halil Özcan and Atatürk University for their invaluable contributions to advancing science and restoring countless patients to a new lease on life. We eagerly anticipate future collaborations and groundbreaking studies. For more insights, visit our website and YouTube channel, and feel free to reach out for treatment protocols and clinical details.

Dr. Barış Ekici, Assistant Professor and Pediatric Neurologist, shares his insights and expertise on transcutaneous vagus nerve stimulation (tVNS) treatment. Vagus nerve stimulation is a technique that stimulates the vagus nerve. It has been approved as a treatment for epilepsy since 1997 and for treatment-resistant depression since 2005. Vagus nerve stimulation creates a pulse that travels from the brainstem to the higher centers in the brain, carrying an electrical signal from the brainstem to the amygdala, hippocampus, and prefrontal cortex. Initially, devices implanted via surgery on the vagus nerve were used. The human ear contains a vast network of nerve stimulations. In particular, branches of the vagus nerve intensively travel to the brain in the concha, the hollow part of the ear. Using this device, we send some repeated stimulations at microampere levels and microsecond intervals to the ear, transmitting a signal from the brainstem to the brain. Vagus nerve stimulation affects the chemicals in the brain and activates the GABAergic system, which we know functions poorly in children with autism. Studies have shown that after vagus nerve stimulation, levels of GABAergic metabolites increase, while glutamate decreases in the cerebrospinal fluid. It also stimulates and regulates serotonergic and noradrenergic systems. Additionally, it calms the brain and reduces neuroinflammation. With vagus nerve stimulation, we expect children with autism to be calmer, more focused, with improved sleep quality, reduced obsessions, and increased speech ability. Our patients' feedback aligns with these expectations. Thanks to modern devices, we now have the opportunity to apply this method to children through the ear, and we have started to see positive effects after one month of stimulation. The good aspect is that, after planning the stimulation according to the child's electroencephalogram (EEG), the family can apply this method at home on their own. We do not observe many side effects. Mild side effects such as ear redness and occasional headaches have been reported. So far, our patients are satisfied with vagus nerve stimulation. Overall, we receive feedback from parents that their child has become calmer, more focused, and has increased speech ability. When activities increase in children with autism, you lose the ability to perform. Therefore, I believe that vagus nerve stimulation, which works from the brainstem to the brain and helps the child find their balance in a calming way, is very suitable for children with autism.

"tVNS therapy in Comatose Patients"  has been a focus research area in recent years in collaboration with esteemed scientists from various countries. The Coma Symposium brought together notable experts, including Prof. Dr. Halil Özcan, Head of the Psychiatry Department at Erzurum Atatürk University, Prof. Dr. Arshad Majid, Head of Neuroscience and Cerebrovascular Neurology at the University of Sheffield, UK, Prof. Armin Bolz, the scientist who has been developing of the patented tVNS technology from Germany, and Selin Erdoğan Gezen, Global Clinical Director at tVNS Health Gmbh. The symposium hosted the discussions on the use of tVNS in comatose patients, sharing clinical experiences, and exploring the future of this therapy. The meeting was held on November 14-15th, under the organization of the Akogo Foundation, committed to providing care at the highest international standards, employing advanced diagnostic tools and neurorehabilitation techniques, in two dedicated "Alarm Clock" Clinics, the first rehabilitation centers for children and adults, in Poland. The event was a highly productive scientific meeting where the use of tVNS in comatose patients across different countries was discussed, patient grou ps who has the potential to benefit from the therapy were identified, and future scientific collaborations and studies were initiated. Sessions also featured case reports from Turkey by esteemed doctors Assoc. Prof. Dr. Burcu Polat and Prof. Dr. Ercan Gürses , highlighting treatments applied to hypoxic patients. These sessions provided inspiration for future treatment protocols. In the coming days, we look forward to sharing the results of a clinical study on the application of tVNS therapy, with the hope that it will inspire and bring new possibilities. We remain committed to offering hope to patients considered untreatable through non-invasive, scientifically supported therapies. Our deepest gratitude goes to our esteemed doctors and scientists for their invaluable contributions to these efforts. A special thank you to Fundacja Ewy Błaszczyk Akogo? for hosting this impactful event and fostering collaboration to advance pediatric care. Together, we’re working towards brighter possibilities. Source: https://www.akogo.pl/pl/aktualnosci/budzik-dla-dzieci/nauka-nie-spi #coma #tvns #vagusnerve #vagusnervestimulation #vnstherapy #vagusnerve #comatose #akogo #stroke #stroketreatment

tVNS Health Gmbh is a medical technology sales company based in Grünwald, Germany, that has been responsible for the global distribution, services, and operations management of tVNS devices. tVNS® in Italy: tVNS Health GmbH | E. M. S. s. r. l tVNS Health GmbH is a medical technology sales company based in Germany, responsible for the global distribution, services, and sales of tVNS® non-invasive auricular vagus nerve stimulation devices in Eastern Europe, Scandinavia, Asia, Africa, South America and Italy. The developer and manufacturer of tVNS® devices is tVNS Technologies GmbH based in Erlangen, Germany. Since the medical approval of the Cerbomed Nemos® device as a first non-invasive auricular vagus nerve stimulation medical device in 2010, Cerbomed Nemos® and the new tVNS® have been used in thousands of treatments globally and significantly improved patients’ quality of life. E.M.S. s.r.l. is a commercial company founded in Bologna in 1994 and ISO-9001 certified. Specializing in the marketing of electromedical equipment and related software systems, the company has established itself as a reliable partner in the field of medical technology. With deep expertise in neuropsychology, neurology, neurorehabilitation, and neurosurgery, E.M.S. offers high-quality, innovative, and exclusive solutions. Thanks to its strong sales network and advanced organizational structure, the company serves both hospitals and neurophysiological research centers with products that exceed standard market quality. In Italy, E.M.S. s.r.l. is the official distributor of tVNS Health GmbH and tVNS Technologies GmbH , providing sales and support services for tVNS® devices and ensuring widespread access to neuromodulation treatments. tVNS Health GmbH Global Sales & Services: Südliche Münchner Str. 62, 82031 Grünwald, Germany info@tvns.health www.tvns.health E. M. S. s. r. l Distributor in Italy Via di Saliceto 81, 40128 Bologna Italy www.emsmedical.net Tel. +39-051396205 Contact Us

tVNS® is a transcutaneous vagus nerve stimulation device for the treatment of symptoms of sympathovagal imbalance. It is approved for epilepsy, autism, insomnia, tinnitus, cognitive impairment, depression and migraine. Changing the World Changing the Lives Elevate your health journey and discover a medication-free, low side effect and non-invasive therapy option for the treatment of neurological diseases. Time to meet a better version of your life. I'm a Patient I’m a Physician I’m a Researcher Become a Distributor Learn more about tVNS Health GmbH tVNS Health GmbH offers worldwide sales and solution services for tVNS® devices for the selected regions , ensuring widespread access to revolutionary neuromodulation treatments across the globe. To play, press and hold the enter key. To stop, release the enter key. tVNS® Devices are Trusted by Leading Institutions Worldwide Why We Lead in Vagus Nerve Stimulation? For over 20 years , our commitment to innovation has positioned us at the forefront of non-invasive vagus nerve stimulation. Our unmatched research and development efforts are backed by solid clinical trials, ensuring our devices are not only effective but also safe and reliable. As an approved Class IIa medical device under the EU-MDR , we offer scientifically validated solutions in a market crowded with unverified alternatives. Since introducing the Cerbomed Nemos® device, we’ve led the market in non-invasive vagus nerve technology. Our pioneering approach and sustained innovation keep us ahead, with our devices being preferred by healthcare professionals and researchers worldwide due to unmatched safety, reliability and precision. Developed and manufactured in Germany, our devices meet the highest quality standards, reflecting our dedication to excellence and the well-being of our patients. Discover tVNS Patient Discover tVNS Research tVNS® In the Media To play, press and hold the enter key. To stop, release the enter key. tVNS® Healing Stories News from tVNS® tVNS Coma Symposium, Warsaw, Poland "tVNS therapy in Comatose Patients" has been a focus research area in recent years in collaboration with esteemed scientists from... Transcutaneous Vagus Nerve Stimulation (tVNS) in Autism. Pediatric neurology specialist Associate Professor Dr. Barış Ekici shares his insights and experiences with transcutaneous vagus nerve stimu Information on tVNS from PD Dr Ranni von Wrede and Dr Pukrowski from Klinik für Epileptologie, UKB Bonn PD. Dr. Ranni von Wrede and Dr. Pukrowski, leading epileptologists from the University of Bonn, discuss the concept of Transcutaneous... A real life epilepsy story of Elena : tVNS in West and Aicardi Syndrome Discover the inspiring journey of Elena, a young girl with Aicardi syndrome and drug-resistant epilepsy, and the positive impact of tVNS... A real life epilepsy story of Oguzhan: tVNS in Dravet Syndrome and Resistant Epilepsy Zeliha Korkmaz, the mother of 7-year-old Oğuzhan, who battles resistant epilepsy and was diagnosed with Dravet syndrome at 4.5 months... Inspiring Insights and 2 coma recovery cases from Prof. Dr. Halil Özcan on Vagus Nerve Stimulation Professor Dr. Halil Özcan, shares insights on his 2 years tVNS experience and 2 coma recovery testimonials Contact Our Global tVNS Experts Worldwide Name Select inquiry: Choose an option Email : Country Please enter you message here Code Phone (optional) I have read and agree to the Privacy Policy Send Thanks for submitting!

tVNS® vagus therapy devices offer a non-surgical neuromodulation treatment option by providing auricular vagus nerve stimulation in difficult-to-treat brain diseases with the help of a smartphone-sized device and a special electrode. tVNS® Devices for Patients Be a part of your success story Buy tVNS Better days are ahead EU-MDR Cla ss IIa Certified Medical Device Non-Invasive Approach Most Effective Stimulation Site Minimal Side Effects tVNS® is the world's only non-invasive vagus nerve stimulation approved as a Class IIa medical device under the EU-MDR, offering a scientifically validated treatment for conditions related to sympathovagal imbalance. A safe and gentle alternative to surgery and medication, tVNS® stimulates the vagus nerve through the skin, offering a harmonious path to wellbeing with very low side-effects. tVNS® is the only non-invasive stimulation device that stimulates the cymba concha, resulting in 100% vagus nerve innervation (as opposed to e.g. the tragus, which only results in 45% innervation). Transitioning away from traditional medications often aims to reduce side effects. tVNS®, as a drug-free therapy, offers a safer alternative with lower risk of long-term adverse effects. tVNS® In the Media To play, press and hold the enter key. To stop, release the enter key. What is tVNS®? Navigating the world of medical treatments can be overwhelming, especially when faced with persistent and challenging health issues. Whether you’ve been tirelessly seeking effective solutions, or if traditional drug therapies have been unsuccessful, there is another option: tVNS® . The vagus nerve, central to our body’s nervous system, plays a critical role in maintaining homeostasis. tVNS®, or Transcutaneous Vagus Nerve Stimulation , harnesses the therapeutic potential of this nerve through targeted stimulation of its auricular branch, accessible within the ear. This innovative approach utilizes gentle electrical impulses to modulate the vagus nerve’s activity, encouraging a state of balance across the body’s systems. The result? A reduction in the symptoms of neurological diseases associated with sympathovagal imbalance, achieved through a method that avoids the invasiveness of surgery and the side effects associated with medication. Approved as a Class IIa medical device under the European Medical Device Regulation (MDR), tVNS® sets a new standard in the treatment of neurological conditions, offering a blend of efficacy, safety, and simplicity. Non-invasive vagus nerve stimulation for the treatment of neurological diseases tVNS® is indicated to treat the following conditions: ✓Anxiety ✓Atrial fibrillation ✓Autism ✓Cognitive Impairment ✓Depression ✓Epilepsy ✓Irritable Bowel Syndrome ✓Inflammatory Bowel Disease ✓Migraines ✓Parkinson's Disease ✓Prader-Willi Syndrome ✓Sleep Disorders ✓Systemic Sclerosis ✓Tinnitus tVNS® Devices are Trusted by Leading Institutions Worldwide To play, press and hold the enter key. To stop, release the enter key. Why choose our tVNS® devices? Our tVNS® device is the only non-invasive vagus nerve stimulator that is approved as a Class IIa medical device under the European Medical Device Regulation (EU-MDR). tVNS® sets itself apart with its non-invasive, clinically validated approach, offering a safer and more comfortable alternative to invasive methods. Uniquely targeting the cymba concha for 100% innervation of the auricular branch of the vagus nerve (ABVN) with our patented electrode, tVNS® ensures maximum efficacy compared to other devices that only achieve partial innervation. EU-MDR Cla ss IIa Approved Medical Device Our tVNS® device is the only non-invasive vagus nerve stimulation (VNS) device that is approved as a medical device under the EU-MDR. It uniquely targets the Cymba Concha for 100% innervation of the auricular branch of the vagus nerve, unlike other devices that stimulate other areas and are not manufactured under the same quality and safety standards. EU-MDR Cla ss IIa Non-Surgical Approach tVNS® offers the efficacy of vagus nerve stimulation without the complexities or risks of surgical interventions. This means meaningful therapeutic benefits, all under your control, without invasive procedures. EU-MDR Cla ss IIa Minimal Side Effects Transitioning away from traditional medications often comes with the pursuit of fewer side effects. tVNS®, being drug-free, ensures a therapeutic experience with reduced potential for long-term adverse outcomes, positioning itself as a safer alternative. EU-MDR Cla ss IIa Made in Germany Our commitment to excellence ensures that each device meets the highest standards of quality and performance, embodying the renowned precision of German engineering and manufacturing. With tVNS®, you’re choosing a device built on a foundation of durability and innovative design, trusted by healthcare professionals and researchers worldwide. EU-MDR Cla ss IIa Innovative App Integration Tracking and understanding your treatment progression is crucial. Our dedicated tVNS® Patient App not only provides real-time monitoring but also facilitates seamless sharing of data with your healthcare professionals. EU-MDR Cla ss IIa Remote Flexibility In our modern age, the convenience of remote access is invaluable. tVNS® extends this by offering device delivery directly to your doorstep and remote training. Initiate your treatment journey without the hassles or constraints of travel. EU-MDR Cla ss IIa Pediatric Compatibility tVNS® has been meticulously designed and approved for use in children aged 3 and above, bridging a crucial gap in pediatric care. EU-MDR Cla ss IIa Easy to Use Functionality should not compromise simplicity. The tVNS® device, while technologically advanced, is as intuitive as a smartphone, making integration into daily routines effortless. How does tVNS® work? With tVNS® ①, light electrical stimulation ④ is given to the vagus nerve ② in the ear ③. These signals are special nerve fibers in the brain stem ⑤ before and then transmitted to the brain via the respective control centers. These stimuli cause the release of neurotransmitters from the brain and increase parasympathetic activity. Treatment with tVNS® is applied by the patient himself. It can be easily integrated into daily life. tVNS ® Patient Devices - tVNS ® E tVNS® vagus therapy devices offer a non-surgical neuromodulation treatment option by providing auricular vagus nerve stimulation in difficult-to-treat brain diseases with the help of a smartphone-sized device and a special electrode. With its innovative mobile application, the patient can share all the treatment information with a single click without leaving his home, and reach the necessary follow-up and support. tVNS® stimulates the branch of the vagus nerve in the auricle through the skin with gentle electrical impulses. Signals are passed on to the brain via special nerve fibers: first in the brain stem and then in higher centers. The treatment with tVNS® is applied by patients independently. It has been used by thousands of patients and is a treatment with very few side effects. Developed and manufactured in Germany, our devices meet the highest quality standards, reflecting our dedication to excellence and the well-being of our patients Download the tVNS® Patient App Track, monitor and share your treatment The innovative tVNS® Patient App is a wellness and session-diary application designed to help users keep a record of their well-being and the duration of their stimulation sessions. The tVNS® Patient App is available now in the Google Play Store and in the Apple App Store (EU-only). tVNS® Patient is fully compliant with the General Data Protection Regulation (GDPR), ensuring that patient data is handled with the utmost care and confidentiality. Clinical Evidence: The Science behind tVNS® Discover the proven effectiveness and safety of tVNS®, highlighted by pivotal clinical trials and studies. Our unique focus on cymba concha stimulation, quality control and clinical evidence, positions tVNS® as the preferred choice among researchers, ensuring we lead in neurotherapeutic innovation and patient care. Epilepsy After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency. Prader-Willi-Syndrome After a treatment period of 12 months, 80% of tVNS® patients recorded a reduction of mean number of outbursts per day of 50%, compared to mean number of outburst per day before treatment. Migraines Treatment with tVNS® led to a reduction of 50% of the frequency of days with migraines after a treatment period of 12 weeks. Depression tVNS® led to a reduction of depression-specific HAMD score of minimum 2-3 points in adult patients when used in parallel with psychopharmacological and psychotherapy treatments after a period of 9 weeks. tVNS Healing Stories Take the next step with tVNS® - for a life without limitations. Every day presents an opportunity. Yet, for those navigating the challenges of medical conditions, some days can feel overshadowed by discomfort or uncertainty. With tVNS® , we aim to bring a brighter shade to every day. By harnessing the power of neurostimulation, our tVNS® device aims to pave the way for more pain-free days, empowering patients to lead self-determined lives. It’s not merely about symptom relief, it’s about reclaiming the essence of each day, savoring moments with loved ones, and pursuing passions without being held back by your condition. tVNS® is approved for the treatment of the following indications. Anxiety Atrial Fibrillation Autism Cognitive Impairment Crohn's disease (IBD) Depression Epilepsy Migraine Parkinson's Prader-Willi Syndrome Sleeping disorders Systematic Sclerosis Tinnitus Contact Our Global tVNS Experts Worldwide Name : Select inquiry: Choose an option Email : Country Please enter you message here Code Phone (optional) I have read and agree to the Privacy Policy Send Thanks for submitting! Contact Our Global tVNS Experts Worldwide Name : Select inquiry Choose an option Email : Country Please enter you message here Code Phone (optional) I have read and agree to the Privacy Policy Send Thanks for submitting!